Hyperactivity

...ba href=/hyperactivity/a/b disorder (ADHD What Customers Are Saying All analyst commentary provided on TradingMarkets.com is provided for educational purposes only.

The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here.

This information is NOT a recommendation or solicitation to buy or sell any securities.

Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use.

Please click the link to view those terms.

Follow this link to read our Editorial Policy.

© 2006 The Connors Group, Inc.

...

...ba href=/hyperactivity/a/b disorder drug Sparlon.

Cephalon wants to market the drug to children ages 6 to 17 with ADHD.

The FDA advisory panel wants Cephalon (NASDAQ: CEPH) of Frazer, Pa., to conduct an additional one-month study to gather more data on a potential side effect: severe skin rashes including a condition known as Stevens Johnson syndrome, a sometimes fatal ailment found in one boy taking the medicine.

Cephalon Founder and CEO Frank Baldino, in a conference call with analysts Thursday night, reiterated his position that the company believes Sparlon is safe and beneficial and side effects are rare.

He said the company was "extremely disappointed" with the advisory panel's decision.

Baldino said company officials will meet with the FDA to determine exactly what additional data the agency wants before committing to conducting any additional studies.

Cephalon also lowered its sales estimate for this year by $100 million to between $1.45 billion and $1.5 billion because of the ruling.

The Securities and Exchange Commission halted trading in Cephalon stock for the entire day Thursday pending the outcome of the advisory panel meeting.

Send us your comments More Latest News ExtraAmerica's pay scales We analyze compensation for jobs in the private sector.

• 10 top-paying jobs • Who gets paid the least • Best-paying blue-collar jobs Related Company stories FDA panel gives thumbs down to Cephalon ADHD drug [Philadelphia] Panel says Cephalon drug is effective but ...

...ba href=/hyperactivity/a/b disorder renamed "Sparlon," on fears of increased suicide risk.

The company's shares, which have bounced around this week, lost $11.25.

or 15.4 percent, to trade at $62.06 on INET, from their Nasdaq close at $73.31.

But while some analysts downgraded the stock, Lawrence H.

Neibor of Baird reiterated an "Outperform," or "Buy" rating on the shares, anticipating a drop in price _ or "severe pressure in the short term" _ he said could benefit investors.

"We recommend using this pressure to buy the stock," Neibor said, although he cut his price target to $75 from $83 to reflect the absence of Sparlon sales in 2008.

"CEPH will work to bring Sparlon to market in this period but we have little confidence," he added.

Subscribe to the paper for less than thirty cents a day!

Copyright Notice & Privacy Policy Place an ad ...